RecruitingPhase 3NCT06836492
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors: a Single Arm Trial.
Sponsor
Yizhuo Zhang
Enrollment
300 participants
Start Date
Jan 30, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Inclusion Criteria6
- years \< age \< 18 years old, regardless of gender;
- Tumor patients diagnosed by histopathology or bone marrow cytology;
- Patients are treated for the first time;
- ECoG score ≤ 2;
- The expected survival time is more than 8 months;
- Patient's parent or guardian signs informed consent.
Exclusion Criteria2
- Combined with immunodeficiency disease
- Second tumor
Interventions
COMBINATION_PRODUCTVAC，VAC/VII，CAV/IE
Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06836492
Related Trials
Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department
NCT072025071 location
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
NCT068656641 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy
NCT074735182 locations
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT066251901 location